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During the past three decades, numerous reports from single-center databases, multicenter
registries, and a few randomized trials in patients with ischemic heart disease (IHD)
undergoing revascularization with both coronary artery bypass grafting and percutaneous
coronary intervention have noted remarkably consistent gender differences in clinical,
angiographic, and procedural factors and an increased morbidity and mortality in women.
Explanations such as alternative markers of atherosclerosis and novel risk factors in women,
gender-specific measures of left ventricular function, and the relationship between disorders
more common in women with IHD and adverse cardiovascular outcomes are beginning to
unfold. (J Am Coll Cardiol 2006;47:63S–5S) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.085Cardiology Foundation
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ihis year, an estimated 150,000 women will undergo
oronary artery bypass grafting (CABG) and 360,000
omen will undergo percutaneous coronary intervention
PCI) for treatment of ischemic heart disease in the U.S.
1). Based upon numerous previous studies (2–4), it is
nticipated that periprocedural mortality and morbidity will
e significantly higher in women in than in men. Most of
his difference in outcomes following revascularization has
een attributed to the older age in women and to the
nderlying gender differences in clinical, angiographic, and
rocedural factors.
In fact, much of what we have learned about the gender
ifferences in patients with IHD has been gleaned from the
umerous studies of patients undergoing coronary revascu-
arization during the past three decades. Single-center
atabases, multicenter registries, and fewer randomized
rials have all reported that when compared with men,
omen have a higher prevalence of risk factors, acute
oronary syndromes, (angina) symptoms, and a higher
revalence of congestive heart failure, despite preservation
f left ventricular (LV) systolic function, but a similar (or
esser) extent of epicardial coronary disease (5,6). Based
pon emerging data from investigations such as the Wom-
n’s Ischemia Syndrome Evaluation (WISE) study (7),
xplanations for these seemingly paradoxic observations
etween the sexes are beginning to unfold.
ave we been looking at the wrong measures of coronary
therosclerosis in women? The Coronary Artery Surgical
tudy (CASS) registry most clearly demonstrated that for a
iven extent of coronary artery disease (single, double, or
riple vessel) measured by angiography, women were more
ymptomatic, had more functional (Canadian Cardiovascu-
ar Society) impairment, and more unstable symptoms than
en (8). Initial skepticism about altered pain threshold and
From the Section of Cardiology, Boston University Medical Center, Boston,a
assachusetts.
Manuscript received November 1, 2004, accepted December 21, 2004.sychologic factors operative in women has gained credence,
nd appropriate evaluation and treatment options are cur-
ently being evaluated (9). In addition, increased apprecia-
ion for syndrome X (chest pain, abnormal (ischemic) stress
est, and normal coronary arteries) is based on the finding of
bnormal coronary flow velocity reserve suggestive of mi-
rovascular dysfunction in women (10). Interestingly, endo-
helial dysfunction due to a higher prevalence of hyperten-
ion and hypercholesterolemia has been implicated as the
asis for the increased chest discomfort in women and for
he presence of chest pain in the absence of significant
oronary artery disease (3). However, aging is associated
ith progressive endothelial dysfunction in both sexes, and
his occurs, in fact, later in women than in men although
here is a steep decline in endothelial function around
enopause (11,12). These findings suggest a gender differ-
nce in the pattern of age-related vascular injury.
ave we been looking at the wrong risk factors for
oronary disease in women? Despite a higher prevalence
f traditional risk factors in women undergoing coronary
evascularization, the extent of epicardial disease is similar
o that seen in men (2–6). In fact, in many series, women
ave a lower prevalence of multivessel disease and fewer
ignificant coronary stenoses. Whether the traditional risk
actors are less potent in women (perhaps based on a
rotective effect of estrogen) or whether women have more
iffuse coronary atherosclerosis is unclear. However, these
ndings have prompted the evaluation of other potential
isk factors or markers of disease in women.
Reports form the WISE study investigators have noted
hat the metabolic syndrome but not obesity (defined by
ody mass index) is associated with significant coronary
rtery disease (13), that apolipoprotein E polymorphism is
n independent risk factor for the presence and severity of
oronary atherosclerosis (14), and that serum amyloid A is
ndependently associated with coronary disease measured by
ngiography in women (15). Additionally, in patients with
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IHD and the Gender Gap February 7, 2006:63S–5Scute coronary syndromes, there is a differential expression
f cardiac biomarkers by gender (16). Specifically, men are
ore likely to have elevated creatine kinase MB and
roponins, whereas women are more likely to have elevated
-reactive protein and brain natriuretic peptide. These data
uggest that there may be gender differences in the patho-
hysiologic mechanisms associated with acute coronary
yndromes. Atherosclerotic plaque rupture, platelet-rich
hrombus, and microembolization may be operative more
ften in men, whereas small-vessel disease, vascular inflam-
ation, and congestive heart failure may be operative more
ften in women (16).
ave we been looking at the wrong measure of LV
unction in women with heart failure? The higher prev-
lence (and incidence) of congestive heart failure despite a
ower prevalence of LV systolic dysfunction (consistent with
ewer previous myocardial infarctions) in women in com-
arison to men undergoing both CABG and PCI has been
ttributed to diastolic dysfunction and hypertensive heart
isease in women (3). In fact, a steeper LV pressure-volume
elationship in women has been reported (17). It is note-
orthy that heart failure is an independent predictor of
ortality following revascularization in both genders (6).
lthough difficult to study because women are under-
epresented in trials of heart failure, owing to older age and
reserved LV function serving as exclusions for enrollment
18), several observations have increased our understanding
f issues specific to women. In elderly patients hospitalized
ith (all-cause) heart failure, female gender is an indepen-
ent predictor of preserved LV systolic function (19).
ypertension, diabetes, and obesity all impart a higher risk,
lthough myocardial infarction appears to impart a lower
isk of heart failure in women than in men (20). Further-
ore, gender differences in postinfarction hypertrophy and
ellular remodeling in end-stage failing hearts have been
eported, with women exhibiting reduced hypertrophy (21).
s there a relationship between the issues specific to
omen with IHD and outcome following coronary re-
ascularization? Although our understanding of the gen-
er differences in outcomes following coronary revascular-
zation has increased, what is missing is a clear concept of
ow these gender paradoxes translate into increased mor-
idity and mortality in women. Recent reports suggest that
mpaired coronary vasomotor response to acetylcholine is
ndependently linked to adverse cardiovascular outcomes
egardless of the severity of coronary atherosclerosis (22),
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CASS  Coronary Artery Surgical Study
IHD  ischemic heart disease
LV  left ventricular
PCI  percutaneous coronary intervention
WISE  Women’s Ischemia Syndrome Evaluationhat the metabolic syndrome modifies the risk associated aith coronary artery disease measured by angiography (23),
nd that lower hemoglobin levels are associated with a
igher risk for adverse outcomes in women undergoing
valuation for ischemic heart disease (24) and in patients
ndergoing PCI (with anemia more frequent in women)
25). It is also noteworthy that in patients with acute
oronary syndromes (16), gender differences in the relation-
hip between elevated biomarkers and outcomes have been
oted. Elevated biomarkers are associated with a benefit
rom early coronary revascularization (compared with early
onservative therapy) in both genders. However, the ab-
ence of at least one positive biomarker is associated with an
ncreased incidence of adverse outcomes in the invasive
ompared with conservatively treated group of women,
hereas there is no difference in outcomes between the two
trategies in men. Finally, LV hypertrophy has been shown
o be an independent predictor of mortality in patients with
oronary artery disease. Although the relative risk of LV
ypertrophy does not vary by race or gender, the attributable
isk is greater in black patients and in women (26).
Whether our increasing appreciation of the issues and
ovel risk factors operative in women will result in contin-
ed improvement in outcomes following both PCI and
ABG remain speculative. What is clear, however, is that
he gender gap in mortality in patients undergoing PCI with
table coronary disease (27), acute coronary syndromes (28),
T-segment elevation myocardial infarction (29), and car-
iogenic shock complicating acute myocardial infarction
30) has narrowed and that the outcomes in women follow-
ng both PCI and CABG have improved (4,27,31).
hether the remaining gender difference in outcomes is
elated to our inability to completely and correctly account
or the inherent biologic differences between the genders has
et to be defined. The fact that stents (32,33) and newer
urgical techniques, including minimal access approaches
34), have not eliminated the gender difference in mortality
ollowing these procedures suggests that periprocedural
omplications are not the major determinant of survival.
ertainly, observations concerning risk-benefit ratios in
omen with acute coronary syndromes where the benefits of
evascularization have been most apparent in those at high
isk (28), in ST-segment elevation myocardial infarction
here the benefit of primary PCI in comparison to fibrino-
ytic therapy has been demonstrated (35), and in cardiogenic
hock where the benefit of revascularization was similar to
hat in men (30) will influence the recommendation of these
herapies to women.
What is missing is a clear understanding of the relation-
hip between symptoms and microvascular ischemia, of the
ender differences in novel risk factors and particularly how
hey relate to the pathophysiology of acute coronary syn-
romes, of the independent relationship between heart
ailure and mortality following revascularization, and of the
mall but persistent gender difference in (adjusted) out-
omes following both CABG and PCI. Fortunately, what is
pparent is that the increasing awareness of the burden of
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February 7, 2006:63S–5S IHD and the Gender Gapardiovascular disease in women has resulted in ongoing
tudies such as those by the WISE study investigators that
ill address what is missing in our understanding of the
ender gap and ultimately improve the care and outcomes in
omen with IHD.
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